Cagrilintide

Description

Cagrilintide is an investigational prescription medication developed by Novo Nordisk, a long-acting synthetic analog of the pancreatic hormone amylin. It is being studied for the treatment of obesity and type 2 diabetes, primarily as a once-weekly subcutaneous injection that mimics amylin’s natural role in regulating appetite and metabolism. By binding to amylin receptors (including subtypes 1 and 3) in the brain and periphery, Cagrilintide enhances satiety signals, slows gastric emptying, reduces food intake, and contributes to meaningful body weight reduction—often with complementary effects on energy balance and insulin sensitivity. As monotherapy in phase 2 trials, Cagrilintide has demonstrated dose-dependent weight loss of approximately 8-10% or more over 26 weeks in adults with overweight or obesity. When combined with semaglutide (branded as CagriSema, a fixed-dose combination of cagrilintide 2.4mg and semaglutide 2.4mg), it leverages synergistic mechanisms: semaglutide’s GLP-1 receptor agonism (insulin stimulation, glucagon suppression, appetite reduction) paired with cagrilintide’s amylin-like effects for amplified outcomes. Phase 2 and ongoing phase 3 trials (including REDEFINE and other programs) report substantial weight reductions exceeding 20% in many participants, along with improvements in cardiometabolic parameters like waist circumference, blood pressure, lipids, and glycemic control in those with type 2 diabetes. Cagrilintide/CagriSema is administered once weekly via pre-filled pen (subcutaneously in the abdomen, thigh, or upper arm), with gradual dose titration to minimize common gastrointestinal side effects such as nausea, vomiting, constipation, decreased appetite, and injection-site reactions, which are typically transient during initiation. As of early 2026, Cagrilintide remains investigational—Novo Nordisk has filed for FDA approval of CagriSema for weight management (with ongoing long-term studies and additional submissions expected), but it is not yet commercially available or approved for general use. Access is limited to clinical trials under strict medical oversight. Potential risks include gastrointestinal intolerance, possible effects on bone metabolism (under study), and theoretical concerns similar to other incretin therapies (e.g., pancreatitis, gallbladder issues, or thyroid effects, though specific profiles are still emerging). It is not recommended during pregnancy, breastfeeding, or in patients with certain gastrointestinal or endocrine conditions. If approved, Cagrilintide/CagriSema could represent a next-generation option for patients seeking more potent appetite suppression and weight loss beyond current GLP-1 therapies. Always consult a healthcare provider for the latest trial updates, eligibility for research programs, or approved alternatives, and never use unapproved or compounded versions due to serious safety risks.

VOIR AUSSI